AMAC and Free2Care Coalition Welcome FTC Investigation into PBMs – AMAC





Free2Care applauds the Federal Trade CommissionThe FTC’s Decision to Investigate the Prescription Drug Intermediary Industry.

The survey requires the six largest Pharmacy Benefit Managers (PBMs) – which control 95% of prescriptions – to provide information and records regarding their business practices.

The Free2VSare coalition and the Association of Mature American Citizens (AMAC) were jointly responsible for nearly three-quarters of the comments the FTC received on the matter.

Senior Vice President of AMAC Action, Andy Mangione issued the following statement in response to the FTC’s vote:

“Americans are fed up with high drug prices and drug shortages that are a direct result of anti-competitive behavior and consolidations between PBMs and insurers.

This is a crucial first step in reforming the system; a clear understanding of how these intermediaries operate would provide transparency and insight into how patients are being harmed.

Free2Care Director David Balat issued the following statement in response to the FTC’s vote:

“Sunlight is the best disinfectant. The FTC must now extend the same investigation to group purchasing organizations (GPOs).

Free2Care will continue to focus on increasing transparency, removing perverse incentives, and creating change that leads to more competition.










If you like articles like this – Subscribe to AMAC’s daily newsletter
and download the AMAC News app

register today
To download


If you like articles like this, subscribe to AMAC’s daily newsletter!











Comments are closed.